Printer Friendly

IMRE CORP. ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY SALES OF PROSORBA COLUMN REACH $2,000,000 FOR THE FIRST TIME

 SEATTLE, Wash., Oct. 13 /PRNewswire/ -- IMRE Corp. (NASDAQ: IMRE) today announced product sales for the quarter ended Sept. 30, 1993 increased 61 percent to $2.01 million compared with $1.25 million for the same period in 1992. The company reported a net loss for the quarter of $0.47 million, or 3 cents per share, compared with a net loss of $1.04 million, or 7 cents per share, for the third quarter of last year. The decreased net loss is due primarily to the increase in sales resulting from increasing acceptance of the PROSORBA(R) column among medical practitioners. Product sales for the nine-month period ended Sept. 30, 1993, increased 60 percent to $5.27 million compared with $3.30 million for the same period in 1992. The company reported a net loss for the nine-month period of $2.75 million, or 19 cents per share, compared with $2.18 million, or 16 cents per share in 1992. The increased loss is due primarily to increased expenditures in marketing and sales and increased research and development activities.
 IMRE Corp. is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA column, has been marketing approved by the Food and Drug Administration and is marketed and sold for the treatment of immune thrombocytopenic purpura (ITP), an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases and certain cancers.
 IMRE Corp.
 Condensed Financial Data
 (In thousands except per share data)
 Three months ended Nine months ended
 Sept. 30, 1993 1992 1993 1992
 Sales $ 2,009 $ 1,251 $ 5,267 $ 3,304
 Interest income 36 91 108 311
 Total revenues 2,045 1,342 5,375 3,615
 Expenses 2,519 2,380 8,123 5,799
 Net loss $ 474 $ 1,038 $ 2,748 $ 2,184
 Net loss per share $ 0.03 $ 0.07 $ 0.19 $ 0.16
 Weighted average
 number of shares
 outstanding during
 the period 15,003 14,017 14,623 14,015
 -0- 10/13/93
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400/
 (IMRE)


CO: IMRE Corp. ST: Washington IN: MTC SU: ERN

JH-RB -- SE008 -- 1745 10/13/93 13:53 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1993
Words:370
Previous Article:BALTIMORE BANCORP REPORTS THIRD QUARTER EARNINGS; REDUCES NONPERFORMING ASSETS BY 25 PERCENT; MEETS FINAL C&D TARGET
Next Article:LEVI STRAUSS ASSOCIATES INC. REPORTS THIRD QUARTER RECORD SALES & STRONG EARNINGS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters